1. Home
  2. AMWD vs ELVN Comparison

AMWD vs ELVN Comparison

Compare AMWD & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

HOLD

Current Price

$57.15

Market Cap

784.1M

ML Signal

HOLD

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

HOLD

Current Price

$17.00

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWD
ELVN
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
784.1M
1.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AMWD
ELVN
Price
$57.15
$17.00
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$64.50
$41.20
AVG Volume (30 Days)
246.3K
661.3K
Earning Date
11-25-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.25
N/A
Revenue
$1,595,658,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.63
N/A
P/E Ratio
$13.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.15
$13.30
52 Week High
$85.74
$25.37

Technical Indicators

Market Signals
Indicator
AMWD
ELVN
Relative Strength Index (RSI) 53.61 33.61
Support Level $52.98 $17.31
Resistance Level $57.67 $20.47
Average True Range (ATR) 2.36 1.39
MACD 0.84 -0.41
Stochastic Oscillator 79.25 6.66

Price Performance

Historical Comparison
AMWD
ELVN

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Share on Social Networks: